Document is current
Any future updates will be listed below
-
Authors
Alkelai, Anna https://orcid.org/0000-0001-6314-8502
Greenbaum, Lior
Docherty, Anna R.
Shabalin, Andrey A.
Povysil, Gundula
Malakar, Ayan
Hughes, Daniel
Delaney, Shannon L.
Peabody, Emma P.
McNamara, James
Gelfman, Sahar
Baugh, Evan H.
Zoghbi, Anthony W.
Harms, Matthew B.
Hwang, Hann-Shyan https://orcid.org/0000-0002-8291-3481
Grossman-Jonish, Anat
Aggarwal, Vimla
Heinzen, Erin L.
Jobanputra, Vaidehi
Pulver, Ann E.
Lerer, Bernard https://orcid.org/0000-0002-9914-632X
Goldstein, David B.
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of Mental Health (5U01MH105670, 5U01MH105670)
U.S. Department of Health & Human Services | NIH | National Institute of Mental Health
- License Information
-
More Information
Article History
Received: 21 April 2021
Revised: 25 October 2021
Accepted: 27 October 2021
First Online: 19 November 2021
Competing interests
: DBG reports holding equity in the publicly traded precision medicine company Praxis Precision Medicine, Apostle Inc, and Q-State Biosciences and has in the past been a paid advisor to AstraZeneca, Gilead Sciences, GoldFinch Bio, and Johnson & Johnson.
